Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and RisksThe epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been spreading globally, raising increasing concerns. This public health emergency has...
We aimed to investigate the efficacy of anti-IL-6 receptor antibody (aIL-6) and other biologic disease-modifying antirheumatic drugs (bDMARDs), such as TNF inhibitor and CTLA4-Ig in the treatment of rheumatoid arthritis (RA) in patients with knee joint involvement. Methods We retrospectively an...
(2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69: 964–975. doi: 10.1136/ard.2009.126532 [7] Doyle MK, Rahman MU, Han C, Han J, Giles J, et al. (2009) Treatment with infliximab ...
Introduction: The new COVID-19 infection is a global problem. In Russia, the 10th version of temporary clinical guidelines allows intravenous administration of anti-IL6 drugs. The aim was to evaluate the effect of anti-IL6 drugs when administered intravenously. Material and methods. 122 patients...
The pattern of anti-IL-6 versus non-anti-IL-6 biologic disease modifying anti-rheumatic drugs use in patients with rheumatoid arthritis in Wales, UK: a real-world study using electronic health recordsrheumatoid arthritisbiologicsIL-6 inhibitorsinfection...
Humanized anti-human IL-6 antibodies and other drugs for increasing serum albumin and reducing C-reactive protein to improve survivability and quality of life of patients.Smith, Jeffrey T L
Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritisdoi:10.1186/s13075-024-03295-9Liu, JianyangIdborg, Helena
This study aimed to analyse the efficacy and safety of interleukin-6 receptor (IL-6Ri) and Janus kinase inhibitors (JAKis), often selected as molecular-targeted drugs for second or subsequent treatments. METHODS. The efficacy and safety of JAKis and IL-6Ri were compared using propensity score...
Humanized anti-human IL-6 antibodies and other drugs for preventing and treating cachexia, weakness, fatigue and/or fever.Smith, Jeffrey T LLatham, JohnLitton, MarkSchatzman, Randall
Atlizumab [Actemra, MRA] is a humanised anti-interleukin-6 receptor monoclonal antibody. It was originated by the Japanese company Chugai Pharmaceutical and is being developed for the treatment of rheumatoid arthritis, Crohn's disease, multiple myelomaARD PROFILEBiodrugs...